A Fundamental Shift in Cancer Care
At Aulos, we’re on a journey to revolutionize cancer patient care through the development of an immune-activating antibody therapeutic that we believe will transform the treatment of cancer. We’re taking on the toughest challenges in immuno-oncology by leveraging artificial intelligence to design a human monoclonal antibody that binds to the portion of interleukin-2 that interacts with the CD25 receptor subunit on regulatory T cells and the vasculature. We believe this therapeutic approach can shift IL-2 activity toward immune activation and away from immune suppression, and prevent the toxic side effects of IL-2, including vascular leak syndrome and pulmonary edema.
Abstracts and Publications
FEATURE
Imneskibart (AU-007), a Human Monoclonal Antibody (mAb) That Binds IL-2 and Prevents CD25 Binding, + Low-Dose Subcutaneous IL-2: Phase 2 Update on CPI-Refractory Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Latest News
Imneskibart: An Investigational Product Candidate
Aulos has initiated the Phase 2 portion of its Phase 1/2 clinical trial of imneskibart in patients with unresectable locally advanced or metastatic solid tumor cancers. The first expansion cohorts will focus on melanoma and renal cell carcinoma.
